Sabeen Shah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sabeen Shah has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Saira Khowaja
Interactive Research and Development (IRD) Global, Singapore 238884, Singapore
2 shared publications - Aamir Khan
Department of Zoology, School of Biological Sciences, Dr Harisingh Gour Vishwavidyalaya (A Central University), Sagar, MP, India
1 shared publication - Aaron Guanliang Lim
Population Health Sciences, Bristol Medical School University of Bristol Bristol UK
1 shared publication Adam Trickey
Population Health Sciences, Bristol Medical School University of Bristol Bristol UK
1 shared publication- Ahmad Nawaz
Interdisciplinary Research Center for Refining & Advanced Chemicals, King Fahd University of Petroleum & Minerals, Dhahran 31261, Saudi Arabia
1 shared publication - Aliya Hasnain
Department of Medicine Aga Khan University Karachi Pakistan
1 shared publication
Latest Publications
- Open Access
- 12 March 2026
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 33 (4) , e70164
Delivering Effective Hepatitis C Virus Treatment in an Embedded Primary Care Setting Within a Tertiary Care Hospital in Karachi, Pakistan
Hepatitis C virus (HCV) endemic regions require accessible treatment interventions. Effectiveness and costs of a pilot HCV treatment programme were evaluated at an embedded primary care service within a tertiary care centre at Indus Hospital and Health Network in Karachi, Pakistan. Data on patients ( n = 1288, median age 40 years) initiating direct‐acting antiviral (DAA) treatment (October 2016 to December 2018) were extracted from hospital records. Eligible patients had chronic HCV, were treatment naïve, and without hepatic decompensation. Multivariable logistic regression analysed factors associated with treatment outcomes (not completing treatment, treatment completion without sustained virological response test at 12 weeks (SVR12) visit, and treatment completion with SVR12). Costs (2019 USD) were estimated using micro‐costing from financial records and staff interviews. Among 1288 patients (63% women), 93% (1200/1288) completed treatment, and 74% (884/1200) attended SVR12 visit, with 98% ( n = 870/884) cured. Compared with 0–29 year‐olds, incomplete treatment was lower among 30–49 year‐olds (aOR 0.47 [0.26–0.83]) and ≥ 50 year‐olds (aOR 0.48 [0.24–0.93]). SVR12 non‐attendance was higher for 24‐week versus 12‐week regimens (aOR: 3.46 [1.51–7.93]), but lower for patients with APRI scores 0.5–1.49 (aOR 0.69 [0.50–0.96]) and ≥ 1.5 (aOR 0.44 [0.24–0.78]) compared to 0–0.49. The mean treatment cost was $370.74 per patient, driven by clinic visits $271.80 (73.3%), labs $68.32 (18.4%), and DAAs $30.62 (8.3%). Overall, a high treatment completion and cure rate were achieved, with a low average cost per patient, indicating that this HCV treatment model can be affordable and may be considered for widescale treatment scale‐up in Pakistan.
- 12 March 2026
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 33 (4) , e70164
Open AccessDelivering Effective Hepatitis C Virus Treatment in an Embedded Primary Care Setting Within a Tertiary Care Hospital in Karachi, Pakistan
Hepatitis C virus (HCV) endemic regions require accessible treatment interventions. Effectiveness and costs of a pilot HCV treatment programme were evaluated at an embedded primary care service within a tertiary care centre at Indus Hospital and Health Network in Karachi, Pakistan. Data on patients ( n = 1288, median age 40 years) initiating direct‐acting antiviral (DAA) treatment (October 2016 to December 2018) were extracted from hospital records. Eligible patients had chronic HCV, were treatment naïve, and without hepatic decompensation. Multivariable logistic regression analysed factors associated with treatment outcomes (not completing treatment, treatment completion without sustained virological response test at 12 weeks (SVR12) visit, and treatment completion with SVR12). Costs (2019 USD) were estimated using micro‐costing from financial records and staff interviews. Among 1288 patients (63% women), 93% (1200/1288) completed treatment, and 74% (884/1200) attended SVR12 visit, with 98% ( n = 870/884) cured. Compared with 0–29 year‐olds, incomplete treatment was lower among 30–49 year‐olds (aOR 0.47 [0.26–0.83]) and ≥ 50 year‐olds (aOR 0.48 [0.24–0.93]). SVR12 non‐attendance was higher for 24‐week versus 12‐week regimens (aOR: 3.46 [1.51–7.93]), but lower for patients with APRI scores 0.5–1.49 (aOR 0.69 [0.50–0.96]) and ≥ 1.5 (aOR 0.44 [0.24–0.78]) compared to 0–0.49. The mean treatment cost was $370.74 per patient, driven by clinic visits $271.80 (73.3%), labs $68.32 (18.4%), and DAAs $30.62 (8.3%). Overall, a high treatment completion and cure rate were achieved, with a low average cost per patient, indicating that this HCV treatment model can be affordable and may be considered for widescale treatment scale‐up in Pakistan.
- 4 July 2022
- Published by Elsevier in Journal of Hepatology
- Vol. 77, S240
Hepatitis C prevalence and elimination in Pakistan; a bottom-up approach accounting for provincial variation
- 4 July 2022
- Published by Elsevier in Journal of Hepatology
- Vol. 77, S240
Hepatitis C prevalence and elimination in Pakistan; a bottom-up approach accounting for provincial variation
- 1 February 2022
- Published by SAGE Publications in Telemedicine and e-Health
- Vol. 28 (2) , 227-232
Proactive Teleconsultation for Coronavirus Disease 2019 Cases Identified Through the Community-Testing Initiative in Karachi, Pakistan: A Low-Cost Value-Added Service to Support a Pandemic Response in a Resource-Limited Setting
Background: Coronavirus disease 2019 (COVID-19) struck Pakistan with a magnitude that required micro- and macro-level adjustments at national and provincial levels. Access to medical consultation became a challenge; hospitals were flooded with cases beyond their capacity and transport was halted due to lockdown. Global Health Directorate of The Indus Health Network supported the provincial government by rolling out several walk-in community-based testing initiatives across Karachi. Results were conveyed to the patients through each district government. With a disproportionate rise in cases, an increasing delay in reporting results was observed. Methods: To help the district government bridge this gap, two physicians were engaged to convey timely results to patients who tested positive, through a helpline. Subsequently, proactive teleconsultation was initiated. We present a retrospective review of data collected during teleconsultation for COVID-19 cases identified through community-based testing between April 5 and June 10, 2020. Results: A total of 4,279 tests were conducted, revealing a 28% positivity rate (1,196 cases). Out of these, 752 (62.9%) baseline positive patients were contactable. Most patients identified either a close contact (46.8%) or a household contact (30.1%) as the source of infection. 41.8% patients were asymptomatic, 52.9% had mild to moderate illness, and 1.1% needed referral to the emergency department. 82.7% patients reported no comorbidities. Conclusion: The rapid surge of cases could not be handled by a small team and an institutional strategy of integration into an existing call center service was adopted. We share our insights to help develop evidence-based policies to effectively tackle current or future threats in similar settings.
- 1 February 2022
- Published by SAGE Publications in Telemedicine and e-Health
- Vol. 28 (2) , 227-232
Proactive Teleconsultation for Coronavirus Disease 2019 Cases Identified Through the Community-Testing Initiative in Karachi, Pakistan: A Low-Cost Value-Added Service to Support a Pandemic Response in a Resource-Limited Setting
Background: Coronavirus disease 2019 (COVID-19) struck Pakistan with a magnitude that required micro- and macro-level adjustments at national and provincial levels. Access to medical consultation became a challenge; hospitals were flooded with cases beyond their capacity and transport was halted due to lockdown. Global Health Directorate of The Indus Health Network supported the provincial government by rolling out several walk-in community-based testing initiatives across Karachi. Results were conveyed to the patients through each district government. With a disproportionate rise in cases, an increasing delay in reporting results was observed. Methods: To help the district government bridge this gap, two physicians were engaged to convey timely results to patients who tested positive, through a helpline. Subsequently, proactive teleconsultation was initiated. We present a retrospective review of data collected during teleconsultation for COVID-19 cases identified through community-based testing between April 5 and June 10, 2020. Results: A total of 4,279 tests were conducted, revealing a 28% positivity rate (1,196 cases). Out of these, 752 (62.9%) baseline positive patients were contactable. Most patients identified either a close contact (46.8%) or a household contact (30.1%) as the source of infection. 41.8% patients were asymptomatic, 52.9% had mild to moderate illness, and 1.1% needed referral to the emergency department. 82.7% patients reported no comorbidities. Conclusion: The rapid surge of cases could not be handled by a small team and an institutional strategy of integration into an existing call center service was adopted. We share our insights to help develop evidence-based policies to effectively tackle current or future threats in similar settings.